Table 1 Clinicopathological and molecular characteristics of the SCAN-B discovery and validation cohorts

From: The DNA methylation landscape of primary triple-negative breast cancer

 

Discovery cohorta

Validation cohorta

Number of patients

 

235

136

Patients assessable for DRFI after adjuvant therapy

 

144

Not applicable

Age (median and range, in years)

 

62 (26–91)

62.5 (30–95)

Lymph node status

 Node-negative (N0)

152 (65%)

87 (69%)

 Node-positive (N+)

83 (35%)

39 (31%)

 Not available

0

10

Nottingham Histologic Grade

 G1

0 (0%)

0 (0%)

 G2

26 (11%)

24 (23%)

 G3

206 (89%)

81 (77%)

 Not available

3

31

PAM50 subtype

 Basal-like

187 (80%)

95 (70%)

 non-Basal-like

48 (20%)

41 (30%)

  1. aPercentages computed excluding missing data. DRFI: distant relapse-free interval.